BIND Biosciences, Inc. Selected for Oral Presentation of BIND-014 Clinical Data at American Association for Cancer Research 2013 Annual Meeting
Published: Mar 26, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced that an oral presentation on its lead drug candidate, BIND-014, has been selected to be presented at the American Association for Cancer Research (AACR) 2013 Annual Meeting taking place April 6-10, 2013 in Washington, DC. The presentation will describe the results of a phase 1 study of BIND-014 in patients with advanced or metastatic solid tumors.